NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Interventional Procedures Advisory Committee

Minutes of the Committee's 169th meeting held at 10:30 on Thursday 10 May 2018 at etc. Venues, Prospero House, Borough High Street, London, SE1 1GA.

PRESENT:

Dr Tom Clutton-Brock (Chair)

Dr Wael Agur

Mr Jonathan Anderson

Mrs Sally Brearley

Dr Chris Carroll

Dr Nicholas Chalmers

Dr Andrew Cook (Vice Chair)

Mr Chris Cunningham

Mrs Rosemary Harris

Mr Anthony Hatswell

Mr Colin Howie

Mr Tim Jackson

Mr Alistair Jenkins

Dr Tim Kinnaird

Dr Neil McGuire

Dr Peter Murphy

Mr Frank Smith

Dr Dhiraj Tripathi

Dr James Tysome

In Attendance NICE Staff:

Miss Hawra Abu Gulal - Programme Manager, IPP

Ms Ria Skelton - Senior Medical Editor

Mrs Helen Gallo- Analyst, IPP

Professor Kevin Harris - Programme Director Clinical Advisor, IPP

Mr Azad Hussain – Administrator, IPP

Miss Chloe Kastoryano - Public Involvement Adviser, PIP Dr Ignacio Malagon - Consultant Clinical Advisor, IPP Professor John Powell, Consultant Clinical Advisor, IPP Ma Doonge Stanisland Administrator (Tomp), IPP

Ms Deonee Stanislaus – Administrator (Temp), IPP

Mrs Vassilia Verdiel - Analyst IPP Mrs Lakshmi Mandava – Analyst IPP Miss Nishat Faruque – Coordinator IPP

Observers: None

Apologies: Dr Zahida Adam

Dr Anthony Emmerson Mr Malcolm Lowe-lauri Mr Mahmoud Elfar Mr Kieran Murphy

Note: The order in which the Committee took items of business at the meeting might differ from the agenda

Meeting started: 10:31

Introduction to the meeting

The Chairman welcomed the Committee Members and observers

The Chairman also welcomed the members of the public and company representatives present at the meeting.

The Chairman announced that this will be Chris Cunningham's last meeting and thanked him for his contribution to IPAC. The Chairman also noted that Nishat Faruque was leaving NICE during May and that it would be her last IPAC meeting..

Code of conduct for members of the public and company representatives attending the meeting

The Chairman outlined the code of conduct for the members of the public and company representatives attending the meeting.

1. Any Other Business

None

2. <u>Minutes of previous meeting</u>

Members accepted these as a correct record.

3. Matters arising

None

4. Agenda changes

The chairman informed the Committee the meeting will run according to the agenda.

5. NICE's Advisory Body guide to declaring a conflict of interest

The Chairman drew the Committee's attention to NICE's advisory body quick guide for declaring conflicts of interest.

6. Newly Notified Procedures

IP998/2 Subcutaneous automated low-flow pump implantation for refractory ascites
The discussion on IP998/2 Subcutaneous automated low-flow pump implantation for
refractory ascites started at 10:38

No conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Andrew Cook and Dhiraj Tripathi

The Chairman declared a Part Two and members of the public as well as company representatives left the meeting at 11:20

The Committee made its provisional recommendations on the safety and efficacy of the procedure.

The discussion on IP998/2 Subcutaneous automated low-flow pump implantation for refractory ascites ended at 11:44

The members of the public as well as company representatives returned at 11:46

IP1690 Ex vivo machine perfusion for extracorporeal preservation of livers for transplantation

The discussion on IP1690 Ex vivo machine perfusion for extracorporeal preservation of livers for transplantation started at 11:46

Dhiraj Tripathi has declared that his hospital have received funding for research for this technology. This was considered an indirect interest and he was allowed to stay for the discussion and decision making.

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Alistair Jenkins and Dhiraj Tripathi

The Chairman declared a Part Two and members of the public as well as company representatives left the meeting at 12:35

The Committee made its provisional recommendations on the safety and efficacy of the procedure.

The discussion on IP1690 Ex vivo machine perfusion for extracorporeal preservation of livers for transplantation ended at 13:00

The members of the public as well as company representatives returned at 13:36.

IP1546 Percutaneous insertion of a temporary catheter-based heart pump for partial/short-term left ventricular hemodynamic support before and during high risk percutaneous coronary interventions.

The discussion on IP1546 Percutaneous insertion of a temporary catheter-based heart pump for partial/short-term left ventricular hemodynamic support before and during high risk percutaneous coronary interventions started at 13:37

No conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Anthony Hatswell and Tim Kinnaird

The Chairman declared a Part Two and members of the public as well as company representatives left the meeting at 14:08

The Committee made its provisional recommendations on the safety and efficacy of the procedure.

The discussion on IP1546 Percutaneous insertion of a temporary catheter-based heart pump for partial/short-term left ventricular hemodynamic support before and during high risk percutaneous coronary interventions ended at 14:42

The members of the public returned at 14:43.

7. Public Consultation comments

IP1568 Superior capsular augmentation for massive rotator cuff tears

The discussion on IP1568 Superior capsular augmentation for massive rotator cuff tears started at 14:44

No conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Colin Howie

The Committee considered the consultation comments

The Chairman declared a Part Two and members of the public left the meeting at 14:47.

The Committee upheld its decision on the safety and efficacy of the procedure

The discussion on IP1568 Superior capsular augmentation for massive rotator cuff tears ended at 14:47

The members of the public as well as company representatives returned to the meeting at 14:49

IP843/2 Transaxial interbody lumbosacral fusion for low back pain

The discussion on IP843/2 Transaxial interbody lumbosacral fusion for low back pain started at 14:50

No conflicts of interest were declared for this procedure
The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Colin Howie

The Committee considered the consultation comments and made changes to section 1.3 in part 1.

The Chairman declared a Part Two and members of the public as well as company representatives left the meeting at 14:56

The Committee upheld its decision on the safety and efficacy of the procedure.

The discussion on IP843/2 Transaxial interbody lumbosacral fusion for low back pain ended at 14:57

The members of the public as well as company representatives returned to the meeting at 14:58.

IP810/2 Low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing

The discussion on IP810/2 Low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing started at 14:59

No conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Colin Howie

The Committee considered the consultation comments.

The following study, identified during consultation, will be added to the main table of the Overview:

Tarride JE, Hopkins RB, Blackhouse G et al (2017). Low-intensity pulsed ultrasound for treatment of tibial fractures: an economic evaluation of the TRUST study. The bone & joint journal (99-B) 11 1526-1532.

The Chairman declared a Part Two and members of the public as well as company representatives left the meeting at 15:05

The Committee upheld its decision on the safety and efficacy of the procedure.

The discussion on IP810/2 Low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing ended at 15:08

The members of the public as well as company representatives returned to the meeting at 15:09

IP1713 Low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing

The discussion on IP1713 Low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing started at 15:10

No conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Colin Howie

The Committee considered the consultation comments

The Chairman declared a Part Two and members of the public as well as company representatives left the meeting at 15:21

The Committee upheld its decision on the safety and efficacy of the procedure.

The discussion on IP1713 Low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing ended at 15:23

The members of the public as well as company representatives returned to the meeting at 15:23

IP1714 Low intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures

The discussion on IP1714 Low intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures started at 15:23

No conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Colin Howie

The Committee considered the consultation comments

The Chairman declared a Part Two and members of the public as well as company representatives left the meeting at 15:35

The Committee upheld its decision on the safety and efficacy of the procedure.

The discussion on IP1714 Low intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures ended at 15:40

There are no members of the public and company representatives present from this point.

8. <u>Briefs of procedures for future assessment</u>

IP1115 Therapeutic cooling following ischaemic stroke

The discussion on IP1115 Therapeutic cooling following ischaemic stroke started at 15:40

The Chair reminded the committee that the equalities and diversity section is in the brief and should be reviewed and commented on as necessary by all the Committee.

Introduced by Tom Clutton-Brock

The Committee advised on the content of the brief for evaluation of this procedure.

The discussion on IP1115 Therapeutic cooling following ischaemic stroke ended at 15:48

IP379/2 Laparoscopic cerclage for cervical incompetence to prevent late miscarriage or preterm birth

The discussion on IP379/2 Laparoscopic cerclage for cervical incompetence to prevent late miscarriage or preterm birth started at 15:48

The Chair reminded the committee that the equalities and diversity section is in the brief and should be reviewed and commented on as necessary by all the Committee.

Introduced by Wael Agur

The Committee advised on the content of the brief for evaluation of this procedure.

The discussion on IP379/2 Laparoscopic cerclage for cervical incompetence to prevent late miscarriage or preterm birth ended at 15:56

IP1550 Endoscopic ablation for an anal fistula

The discussion on IP1550 Endoscopic ablation for an anal fistula started at 15:57

The Chair reminded the committee that the equalities and diversity section is in the brief and should be reviewed and commented on as necessary by all the Committee.

Introduced by Chris Cunningham

Anthony Hatswell declared he is working with Takeda on a drug used to treat anal fistula. This was considered an indirect interest and he stayed for the discussion.

Tom Clutton-Brock declared his institution has received funding from the NIHR as a coapplicant on developing a device to treat anal fistula. This was considered an indirect interest and he stayed for the discussion.

The Committee advised on the content of the brief for evaluation of this procedure.

The discussion on IP1550 Endoscopic ablation for an anal fistula ended at 16:06

IP1729 Endoscopic pilonidal sinus treatment (EPSiT)

The discussion on IP1729 Endoscopic pilonidal sinus treatment (EPSiT) started at 16:06

The Chair reminded the committee that the equalities and diversity section is in the brief and should be reviewed and commented on as necessary by all the Committee.

Introduced by Chris Cunningham

The Committee advised on the content of the brief for evaluation of this procedure.

The discussion on IP1729 Endoscopic pilonidal sinus treatment (EPSiT) ended at 16:14

9. Other meeting matters

None

10. <u>Date of the next meeting</u>

The 170th meeting of the Interventional Procedures Advisory Committee will be held on Thursday 14th June 2018, and will start promptly at 1030. The meeting will be held at 10 Spring Gardens, London, SW1A 2BU

The meeting ended at 16:15